For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

BPC-157

Also known as: Body Protection Compound 157, PL 14736

Research use only · not FDA-approved

Pentadecapeptide derived from a gastric protective protein. Studied for tendon/ligament healing, GI tract repair, and angiogenesis via VEGFR2 pathway interaction.

Where to buy · live market data

Who's worth your money for BPC-157

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 28 scored sellers

$2.30/mg

$45.99 · 20mg · 100.0% purity

10 COAs
Buy code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$2.25/mg

$450 · 200mg · 99.3% purity

Most tested

91 independent COAs on file

$5.30/mg

$53.00 · 10mg · 99.8% purity

Average price

$9.39/mg

Sellers

91

45-day trend

-7.7%

71 of 91 sellers have a current price· 15 stale hidden· 28 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch BPC-157

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About BPC-157

CAS

137525-51-0

Molecular formula

C62H98N16O22

Sequence

GEPPPGKPADDAGLV

Typical dose range

200-500 mcg/day subcutaneous or intramuscular

Half-life

<30 minutes (IV: ~15 min in rats, ~5 min in dogs)

Common research uses

tendon and ligament injury recoverygastrointestinal ulcer healing (animal studies)post-surgical recovery (research only)

Safety notes

Not FDA-approved for human therapeutic use. WADA does not currently prohibit BPC-157 but research-use only status applies in most jurisdictions.

Reconstitution

Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.

Independent evidence

COAs for BPC-157

467 third-party tests across 43 vendors. Each card links to the full report.

All 467 COAs for BPC-157 →
Measured purity 76.3%–100.0% across 291 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.90 %
Jul 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC10-08

Aggregated · 3rd-party listing
99.91 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch 148-01-DK

✓ Vendor-published
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BCS-06242026

COA on file
Aggregated · 3rd-party listing
99.91 %
Jun 2026
ILS Labs Strong

For

BPC-157

by Orbitrex Peptides· batch BPC10726US

Aggregated · 3rd-party listing
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BC5-06242026

Aggregated · 3rd-party listing
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by Optima Supply· batch OS-2026-3074

Aggregated · 3rd-party listing
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by Hydro Research Peptides· batch HR-2026-4512

Aggregated · 3rd-party listing
99.33 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Apexx Biolabs· batch Black Cap-1

✓ Vendor-published
99.80 %
Jun 2026
TrustPointe Analytics Moderate

For

BPC-157

by Peptide Partners· batch SPL-4161

COA on file
✓ Vendor-published
99.43 %
Jun 2026
MZ Biolabs Moderate

For

BPC-157 (Bepecin) Arginine Salt

by Sports Technology Labs· batch 2026-05-30

COA on file
Aggregated · 3rd-party listing
99.96 %
Jun 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC20-05

Aggregated · 3rd-party listing
99.11 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch GGB-03-BL

Aggregated · 3rd-party listing
99.86 %
Jun 2026
ILS Labs Strong

For

BPC-157

by Crush Research· batch CRBPC-10-2605-1

Aggregated · 3rd-party listing
99.50 %
May 2026
Freedom Diagnostics Moderate

For

BPC-157

by Secra Labs· batch SL-202605-BPC157

✓ Vendor-published
99.84 %
May 2026
ILS Laboratories

For

BPC-157

by Ion Peptide· batch BPC10-05202026

COA on file
✓ Vendor-published
99.36 %
May 2026
Kovera Labs

For

BPC-157

by Ion Peptide· batch BC10-05122026

COA on file
Aggregated · 3rd-party listing
99.78 %
May 2026
Janoshik Analytical Limited

For

BPC-157

by Verified Peptides· batch BP06261310K

Aggregated · 3rd-party listing
99.93 %
May 2026
Janoshik Analytical Limited

For

BPC-157

by EZ Peptides· batch EZP - BPC1005082026-22

✓ Vendor-published
99.93 %
May 2026
Janoshik Analytical Limited

For

BPC-157

by EZ Peptides· batch EZP - BPC1005082026-22

COA on file
Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics Strong · HPLC

For

BPC-157

by OROS Research· batch OR-LPBPC5-526-B5

Aggregated · 3rd-party listing
99.36 %
May 2026
Horizon Analytical

For

BPC-157

by Pepsgpt· batch P-7454331-P

Aggregated · 3rd-party listing
99.22 %
May 2026
ILS Labs Strong

For

BPC-157

by Ion Peptide· batch BC20-05070206

Aggregated · 3rd-party listing
99.81 %
May 2026
Janoshik Analytical Limited · HPLC

For

BPC-157

by Prime Peptides· batch 4042026BP

✓ Vendor-published
99.74 %
May 2026
TrustPointe Analytics Moderate

For

BPC-157/TB-500

by Peptide Partners· batch SPL-3799

COA on file
Research depth

19 citations indexed for BPC-157

All research on BPC-157 →

Study · 2026

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase

Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease.

animal · 2026

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach

Background . This rat study reveals a new point: the considerable impact of unilateral adrenalectomy, severe vascular and multiorgan failure, occlusion/occlusion-like syndrome, and the stable gastric pentadecapeptide BPC 157 therapy.

animal · 2026

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury

Ischemia-reperfusion (I/R) injury remains a major complication in peripheral arterial disease, characterized by oxidative stress, inflammation, and apoptosis. Body Protection Compound-157 (BPC 157), a stable gastric pentadecapeptide, has demonstrated cytoprotective properties in multiple tissues.

review · 2026

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers

Background/Objectives : BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems.

review · 2026

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from gastric proteins that has demonstrated notable reparative and anti-inflammatory properties across diverse preclinical models.

review · 2026

Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics

This review presents an innovative and timely exploration of how cytoprotection can serve as a cohesive therapeutic approach by which to address the hemorrhage-thrombosis paradox.

Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.